Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - hulgiskleroos - immunosupressandid - täiskasvanud patsientidel, kellel on kliinilistes või pildistamisfunktsioonides määratletud aktiivne haigus koos hulgiskleroosiga (rms). ravi täiskasvanud patsientidel varajases primaarne progresseeruv sclerosis multiplex (ppms) seoses haiguse kestus ja puude, ja koos pildistamine funktsioone iseloomulik põletikuline aktiivsus.

Eesti - eesti - Ravimiamet

roche diagnostics gmbh - okrelizumab - infusioonilahuse kontsentraat - 30mg 1ml 10ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - ravimid hingamisteede obstruktiivsete haiguste, - allergiline asthmaxolair on näidustatud täiskasvanud, noorukid ja lapsed (6 kuni.

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - soliris on näidatud täiskasvanute ja laste raviks:paroxysmal öise haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5. ebatüüpiline hemolüütilis-ureemilise sündroomi (ahus). soliris on näidustatud täiskasvanute raviks:tulekindlad generaliseerunud myasthenia gravis (gmg) patsientidel, kes on anti-atsetüülkoliin retseptori (achr) antikeha-positiivsete (vt lõik 5. neuromyelitis optica spectrum disorder (nmosd) patsientidel, kes on anti-aquaporin-4 (aqp4) antikeha-positiivsete koos relapsing haiguse kulg.

Euroopa Liit - eesti - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Eesti - eesti - Ravimiamet

stallergenes - heintaimede õietolm - keelealune tablett - 300ir 90tk; 300ir 30tk

Eesti - eesti - Ravimiamet

stallergenes - heintaimede õietolm - keelealune tablett - 100ir/300ir 3tk / 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.